{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:18:51Z","timestamp":1780413531245,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03275-w","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:10:40Z","timestamp":1771423840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metronomic chemotherapy in resource-limited settings: evidence, opportunities, and future directions"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8743-831X","authenticated-orcid":false,"given":"Atul Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"6","key":"3275_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3275_CR2","unstructured":"Wild CP, Weiderpass E, Stewart BW, editors. World Cancer Report: Cancer research for cancer prevention [Internet]. Lyon (FR): International Agency for Research on Cancer; 2020 [cited 2025 Aug 29]. (IARC s). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606505\/"},{"issue":"6","key":"3275_CR3","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1016\/S1470-2045(13)70056-1","volume":"14","author":"N Andr\u00e9","year":"2013","unstructured":"Andr\u00e9 N, Banavali S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 2013;14(6):e239\u2013248.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3275_CR4","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1016\/j.ejca.2013.03.024","volume":"49","author":"S Gupta","year":"2013","unstructured":"Gupta S, Yeh S, Martiniuk A, Lam CG, Chen HY, Liu YL, et al. The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: a systematic review and meta-analysis. Eur J Cancer. 2013;49(11):2555\u201364.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3275_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","volume":"20","author":"C Barrios","year":"2023","unstructured":"Barrios C, de Lima Lopes G, Yusof MM, Rubagumya F, Rutkowski P, Sengar M. Barriers in access to oncology drugs - a global crisis. Nat Rev Clin Oncol. 2023;20(1):7\u201315.","journal-title":"Nat Rev Clin Oncol"},{"key":"3275_CR6","unstructured":"(PDF) Cancer Care in Resource-Limited Settings: A Call for Action [Internet]. [cited 2025 Aug 29]. Available from: https:\/\/www.researchgate.net\/publication\/236964208_Cancer_Care_in_Resource-Limited_Settings_A_Call_for_Action"},{"issue":"6","key":"3275_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3275_CR8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","volume":"7","author":"E Pasquier","year":"2010","unstructured":"Pasquier E, Kavallaris M, Andr\u00e9 N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7(8):455\u201365.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"3275_CR9","first-page":"208","volume":"7","author":"J Satti","year":"2009","unstructured":"Satti J. The emerging low-dose therapy for advanced cancers. Dose-Response Publ Int Hormesis Soc. 2009;7(3):208\u201320.","journal-title":"Dose-Response Publ Int Hormesis Soc"},{"key":"3275_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5483791","volume":"2019","author":"C Simsek","year":"2019","unstructured":"Simsek C, Esin E, Yalcin S. Metronomic chemotherapy: a systematic review of the literature and clinical experience. J Oncol. 2019;2019:5483791.","journal-title":"J Oncol"},{"issue":"3","key":"3275_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/fon.11.11","volume":"7","author":"N Andr\u00e9","year":"2011","unstructured":"Andr\u00e9 N, Padovani L, Pasquier E. Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol. 2011;7(3):385\u201394.","journal-title":"Future Oncol"},{"key":"3275_CR12","unstructured":"Menestrel ML, Le Marc M. 2025 [cited 2025 Aug 29]. Metronomics Global Health Initiative. Available from: http:\/\/ww.marc-lemenestrel.net\/Metronomics-Global-Health.html"},{"issue":"7","key":"3275_CR13","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kr\u00e4ling BM, Shi B, Marshall B, O\u2019Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental Drug-resistant Cancer1. Cancer Res. 2000;60(7):1878\u201386.","journal-title":"Cancer Res"},{"issue":"7","key":"3275_CR14","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kr\u00e4ling BM, Shi B, Marshall B, O\u2019Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878\u201386.","journal-title":"Cancer Res"},{"issue":"15","key":"3275_CR15","first-page":"4342","volume":"63","author":"F Bertolini","year":"2003","unstructured":"Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of Circulating endothelial progenitor cells. Cancer Res. 2003;63(15):4342\u20136.","journal-title":"Cancer Res"},{"issue":"5","key":"3275_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","volume":"64","author":"Y Hamano","year":"2004","unstructured":"Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004;64(5):1570\u20134.","journal-title":"Cancer Res"},{"issue":"5","key":"3275_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","volume":"56","author":"F Ghiringhelli","year":"2007","unstructured":"Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641\u20138.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"3275_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358(2):100\u20136.","journal-title":"Cancer Lett"},{"issue":"4","key":"3275_CR19","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12663-023-01963-y","volume":"23","author":"NAN Kumar","year":"2024","unstructured":"Kumar NAN, Dikhit PS, Jose A, Mehta V, Pai A, Kudva A, et al. Oral metronomic chemotherapy in advanced and metastatic oral squamous cell carcinoma: A need of the hour. J Maxillofac Oral Surg. 2024;23(4):793\u2013800.","journal-title":"J Maxillofac Oral Surg"},{"issue":"9","key":"3275_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092236","volume":"13","author":"ME Cazzaniga","year":"2021","unstructured":"Cazzaniga ME, Cordani N, Capici S, Cogliati V, Riva F, Cerrito MG. Metronomic Chemotherapy. Cancers. 2021;13(9):2236.","journal-title":"Cancers"},{"key":"3275_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3332\/ecancer.2016.689","volume":"10","author":"P Pantziarka","year":"2016","unstructured":"Pantziarka P, Hutchinson L, Andr\u00e9 N, Benzekry S, Bertolini F, Bhattacharjee A, et al. Next generation metronomic chemotherapy\u2014report from the fifth biennial international metronomic and Anti-angiogenic therapy Meeting, 6\u20138 May 2016, Mumbai. Ecancermedicalscience. 2016;10:689.","journal-title":"Ecancermedicalscience"},{"key":"3275_CR22","doi-asserted-by":"crossref","unstructured":"Devi RN, Menon A, Shenoy PK, Avaronnan M, Shahana S, George A. Oral Metronomic Therapy: An Effective Palliative Treatment Option for Epithelial Ovarian Cancer. Cureus [Internet]. 2024 Nov 6 [cited 2025 Aug 29]; Available from: https:\/\/www.cureus.com\/articles\/310185-oral-metronomic-therapy-an-effective-palliative-treatment-option-for-epithelial-ovarian-cancer","DOI":"10.7759\/cureus.73171"},{"issue":"20","key":"3275_CR23","first-page":"5128","volume":"14","author":"I Slavc","year":"2022","unstructured":"Slavc I, Mayr L, Stepien N, Gojo J, Aliotti Lippolis M, Azizi AA, et al. Improved Long-Term survival of patients with recurrent Medulloblastoma treated with a MEMMAT-like. Metronomic Antiangiogenic Approach Cancers. 2022;14(20):5128.","journal-title":"Metronomic Antiangiogenic Approach Cancers"},{"key":"3275_CR24","doi-asserted-by":"publisher","first-page":"216617","DOI":"10.1016\/j.canlet.2024.216617","volume":"588","author":"SW Chou","year":"2024","unstructured":"Chou SW, Chang HH. Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma. Cancer Lett. 2024;588:216617.","journal-title":"Cancer Lett"},{"key":"3275_CR25","unstructured":"Exceptional response to. oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma - ecancer [Internet]. [cited 2025 Aug 29]. Available from: https:\/\/ecancer.org\/es\/journal\/article\/1287-exceptional-response-to-oral-metronomic-chemotherapy-in-a-rare-case-of-sinonasal-mucosal-melanoma"},{"issue":"3","key":"3275_CR26","doi-asserted-by":"publisher","first-page":"e24670","DOI":"10.1016\/j.heliyon.2024.e24670","volume":"10","author":"N Jan","year":"2024","unstructured":"Jan N, Sofi S, Qayoom H, Shabir A, Haq BU, Macha MA, et al. Metronomic chemotherapy and drug repurposing: a paradigm shift in oncology. Heliyon. 2024;10(3):e24670.","journal-title":"Heliyon"},{"issue":"4","key":"3275_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1593\/tlo.11124","volume":"4","author":"E Pasquier","year":"2011","unstructured":"Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd international workshop on metronomic and anti-angiogenic chemotherapy in paediatric oncology. Transl Oncol. 2011;4(4):203\u201311.","journal-title":"Transl Oncol"},{"key":"3275_CR28","doi-asserted-by":"publisher","first-page":"e2300308","DOI":"10.1200\/GO.23.00308","volume":"10","author":"J Bajpai","year":"2024","unstructured":"Bajpai J, Munot P, Kota K, Gupta G, Gala K, Gulia A, et al. Evaluation of metronomic therapy as a low-cost, sustainable, standard-of-care option in desmoid fibromatosis: real-world data from a tertiary care center in India. JCO Glob Oncol. 2024;10:e2300308.","journal-title":"JCO Glob Oncol"},{"key":"3275_CR29","doi-asserted-by":"publisher","unstructured":"She L, Tian K, Han J, Zuo W, Wang Z, Zhang N. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol [Internet]. 2022 Sept 13 [cited 2026 Jan 15];12. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2022.904372\/full","DOI":"10.3389\/fonc.2022.904372\/full"},{"key":"3275_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.904372","volume":"12","author":"L She","year":"2022","unstructured":"She L, Tian K, Han J, Zuo W, Wang Z, Zhang N. Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol. 2022;12:904372.","journal-title":"Front Oncol"},{"issue":"9","key":"3275_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092471","volume":"15","author":"E Muraro","year":"2023","unstructured":"Muraro E, Vinante L, Fratta E, Bearz A, H\u00f6fler D, Steffan A, et al. Metronomic chemotherapy: anti-tumor pathways and combination with immune checkpoint inhibitors. Cancers. 2023;15(9):2471.","journal-title":"Cancers"},{"key":"3275_CR32","volume":"6","author":"JL Vitorino-Araujo","year":"2020","unstructured":"Vitorino-Araujo JL, Lopes AB, de Melo AC. Metronomic chemotherapy in resource-limited settings: a review. JCO Glob Oncol. 2020;6:JGO.19.00288.","journal-title":"JCO Glob Oncol"},{"issue":"10","key":"3275_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2471\/BLT.15.163998","volume":"94","author":"J Robertson","year":"2016","unstructured":"Robertson J, Barr R, Shulman LN, Forte GB, Magrini N. Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ. 2016;94(10):735\u201342.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"3275_CR34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/tbj.12357","volume":"21","author":"BO Anderson","year":"2015","unstructured":"Anderson BO, Ilbawi AM, El Saghir NS. Breast cancer in low and middle income countries (LMICs): a shifting tide in global health. Breast J. 2015;21(1):111\u20138.","journal-title":"Breast J"},{"key":"3275_CR35","unstructured":"Regulation. and Prequalification [Internet]. [cited 2025 Aug 29]. Available from: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance"},{"issue":"16","key":"3275_CR36","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.ejca.2013.06.038","volume":"49","author":"K Lien","year":"2013","unstructured":"Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387\u201395.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3275_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1358\/dnp.2010.23.2.1475913","volume":"23","author":"N Andr\u00e9","year":"2010","unstructured":"Andr\u00e9 N, Padovani L, Verschuur A. Metronomic chemotherapy: back to the future! Drug News Perspect. 2010;23(2):143\u201351.","journal-title":"Drug News Perspect"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03275-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:04:18Z","timestamp":1775649858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03275-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["3275"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03275-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}